{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T03:57:25Z","timestamp":1794455845275,"version":"4.9.1"},"reference-count":217,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.biopha.2025.118023","type":"journal-article","created":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T21:10:25Z","timestamp":1743541825000},"page":"118023","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":98,"special_numbering":"C","title":["Targeting VEGF signaling for tumor microenvironment remodeling and metastasis inhibition: Therapeutic strategies and insights"],"prefix":"10.1016","volume":"186","author":[{"given":"Hanie","family":"Mahaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sima","family":"Nobari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamid","family":"Tanzadehpanah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Babaeizad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gholamhosein","family":"Kazemzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsen","family":"Mehrabzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arezoo","family":"Valipour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nader","family":"Yazdinezhad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamed","family":"Manoochehri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsen","family":"Sheykhhasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2025.118023_bib1","doi-asserted-by":"crossref","first-page":"1442888","DOI":"10.3389\/fphar.2024.1442888","article-title":"Tumor microenvironment and cancer metastasis: molecular mechanisms and therapeutic implications","volume":"15","author":"Biray Avci","year":"2024","journal-title":"Front Pharm."},{"issue":"1-2","key":"10.1016\/j.biopha.2025.118023_bib2","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s10555-011-9337-5","article-title":"Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer","volume":"31","author":"Masoumi Moghaddam","year":"2012","journal-title":"Cancer Metastas-.-. Rev."},{"issue":"5","key":"10.1016\/j.biopha.2025.118023_bib3","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","article-title":"Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges","volume":"15","author":"Fukumura","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.biopha.2025.118023_bib4","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a006577","article-title":"Anti-VEGF therapies in the clinic","volume":"2","author":"Meadows","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med"},{"key":"10.1016\/j.biopha.2025.118023_bib5","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3389\/fonc.2020.00221","article-title":"Resistance mechanisms to anti-angiogenic therapies in cancer","volume":"10","author":"Haibe","year":"2020","journal-title":"Front Oncol."},{"issue":"6","key":"10.1016\/j.biopha.2025.118023_bib6","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/s41571-024-00886-y","article-title":"Antiangiogenic-immune-checkpoint inhibitor combinations: lessons from phase III clinical trials","volume":"21","author":"Kuo","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.biopha.2025.118023_bib7","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/nm0603-669","article-title":"The biology of VEGF and its receptors","volume":"9","author":"Ferrara","year":"2003","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.biopha.2025.118023_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e41346","article-title":"Global perspectives and hotspots of VEGF signaling pathway in liver disease from 2008 to 2023: a bibliometric analysis and visualization","volume":"11","author":"He","year":"2025","journal-title":"Heliyon"},{"issue":"1","key":"10.1016\/j.biopha.2025.118023_bib9","doi-asserted-by":"crossref","first-page":"189","DOI":"10.17305\/bb.2024.10794","article-title":"F13B regulates angiogenesis and tumor progression in hepatocellular carcinoma via the HIF-1\u03b1\/VEGF pathway","volume":"25","author":"Jiang","year":"2024","journal-title":"Biomol. Biomed."},{"issue":"1","key":"10.1016\/j.biopha.2025.118023_bib10","doi-asserted-by":"crossref","first-page":"120","DOI":"10.14740\/wjon1993","article-title":"VEGFA gene expression in breast cancer is associated with worse prognosis, but better response to chemotherapy and immunotherapy","volume":"16","author":"Sharma","year":"2025","journal-title":"World J. Oncol."},{"issue":"9","key":"10.1016\/j.biopha.2025.118023_bib11","doi-asserted-by":"crossref","first-page":"3845","DOI":"10.7150\/ijbs.70958","article-title":"VEGF\/VEGFR-targeted therapy and immunotherapy in non-small cell lung cancer: targeting the tumor microenvironment","volume":"18","author":"Zhao","year":"2022","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.biopha.2025.118023_bib12","first-page":"1","article-title":"The co-receptor Neuropilin-1 enhances proliferation in inv (16) acute myeloid leukemia via VEGF signaling","author":"Hegde","year":"2024","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.biopha.2025.118023_bib13","article-title":"effect of polymorphisms of Vascular Endothelial Growth Factor (VEGF) and transforming growth factor beta-1 (tgf-\u03b21) in women with recurrent miscarriage","volume":"14","author":"Washel","year":"2024","journal-title":"J. Educ. Pure Sci. -Univ. Thi-Qar"},{"key":"10.1016\/j.biopha.2025.118023_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2024.122563","article-title":"VEGF\/VEGFR axis and its signaling in melanoma: current knowledge toward therapeutic targeting agents and future perspectives","author":"Malekan","year":"2024","journal-title":"Life Sci."},{"issue":"12","key":"10.1016\/j.biopha.2025.118023_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0316035","article-title":"Plasma and serum concentrations of VEGF-A121, but not of VEGF-A165, increase post-bevacizumab administration","volume":"19","author":"Okawa","year":"2024","journal-title":"PloS One"},{"key":"10.1016\/j.biopha.2025.118023_bib16","unstructured":"Lee H.N., Seo C.E., Jeong M.S., Jang S.B. The Molecular Insight into the Vascular Endothelial Growth Factor in Cancer: Angiogenesis and Metastasis. \uc0dd\uba85\uacfc\ud559\ud68c\uc9c0. 2024;34(2):128-137."},{"issue":"16","key":"10.1016\/j.biopha.2025.118023_bib17","doi-asserted-by":"crossref","first-page":"8855","DOI":"10.3390\/ijms25168855","article-title":"A splice form of VEGF, a potential anti-angiogenetic form of head and neck squamous cell cancer inhibition","volume":"25","author":"Dumitru","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"19","key":"10.1016\/j.biopha.2025.118023_bib18","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.3390\/ani14192771","article-title":"Melatonin regulates the expression of VEGF and HOXA10 in bovine endometrial epithelial cells through the SIRT1\/PI3K\/AKT pathway","volume":"14","author":"Li","year":"2024","journal-title":"Animals"},{"issue":"6","key":"10.1016\/j.biopha.2025.118023_bib19","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.3390\/biomedicines12061328","article-title":"Increase in vascular endothelial growth factor (VEGF) Expression and the Pathogenesis of iMCD-TAFRO","volume":"12","author":"Srkalovic","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.biopha.2025.118023_bib20","series-title":"Therapeutic Applications of Nitric Oxide in Cancer and Inflammatory Disorders","first-page":"59","article-title":"Preclinical models to assess the pharmacological properties of NO derivatives","author":"Morbidelli","year":"2025"},{"issue":"10","key":"10.1016\/j.biopha.2025.118023_bib21","article-title":"Hypoxia-inducible Factor 1-alpha (hif-1\u03b1) and Cancer: Mechanisms of Tumor Hypoxia and Therapeutic Targeting","volume":"16","author":"Basheeruddin","year":"2024","journal-title":"Cureus"},{"issue":"17","key":"10.1016\/j.biopha.2025.118023_bib22","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.3390\/diagnostics14171909","article-title":"Genetics, Pathophysiology, and current challenges in von hippel\u2013lindau disease therapeutics","volume":"14","author":"G\u00f3mez-Virgilio","year":"2024","journal-title":"Diagnostics"},{"issue":"11","key":"10.1016\/j.biopha.2025.118023_bib23","doi-asserted-by":"crossref","first-page":"390","DOI":"10.31083\/j.fbl2911390","article-title":"The PLCG2 inhibits tumor progression and mediates angiogenesis by VEGF signaling pathway in clear cell renal cell carcinoma","volume":"29","author":"Zhao","year":"2024","journal-title":"Front. Biosci. -Landmark"},{"key":"10.1016\/j.biopha.2025.118023_bib24","article-title":"Food-derived phytochemicals from functional food (Allium sativum) as VEGF-R1 inhibitors: a novel approach for triple-negative breast cancer therapy","author":"Mahboob","year":"2024","journal-title":"Food Biosci."},{"key":"10.1016\/j.biopha.2025.118023_bib25","article-title":"De novo drug design and repurposing to suppress liver cancer via VEGF-R1 mechanism: comprehensive molecular docking, molecular dynamics simulations and ADME estimation","author":"Agar","year":"2024","journal-title":"Med. Chem."},{"issue":"23","key":"10.1016\/j.biopha.2025.118023_bib26","article-title":"Vascular endothelial growth factor and the pathogenesis of intracranial aneurysms: a systematic review on the missing link in a complex pathway","volume":"13","author":"Nisson","year":"2024","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.biopha.2025.118023_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.fitote.2024.106100","article-title":"Effects of natural products on angiogenesis in melanoma","author":"Wang","year":"2024","journal-title":"Fitoterapia"},{"key":"10.1016\/j.biopha.2025.118023_bib28","doi-asserted-by":"crossref","unstructured":"Kokkotou E., Charpidou A.G., Syrigos N.K. Predictive Value of Serum VEGF Levels in Non-Small Cell Lung Cancer: A. 2024.","DOI":"10.20944\/preprints202409.1475.v1"},{"issue":"7","key":"10.1016\/j.biopha.2025.118023_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2024.102408","article-title":"Vildagliptin ameliorates intrapulmonary vasodilatation and angiogenesis in chronic common bile duct ligation-induced hepatopulmonary syndrome in rat","volume":"48","author":"Mangoura","year":"2024","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"10.1016\/j.biopha.2025.118023_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2024.136938","article-title":"3D-printed biomimetic bone scaffold loaded with lyophilized concentrated growth factors promotes bone defect repair by regulation the VEGFR2\/PI3K\/AKT signaling pathway","volume":"282","author":"Liu","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118023_bib31","doi-asserted-by":"crossref","first-page":"28327","DOI":"10.1038\/s41598-024-78126-7","article-title":"Catalpol regulates apoptosis and proliferation of endothelial cell via activating HIF-1\u03b1\/VEGF signaling pathway","volume":"14","author":"Ni","year":"2024","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.biopha.2025.118023_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-024-02137-1","article-title":"Prostate cancer microenvironment: multidimensional regulation of immune cells, vascular system, stromal cells, and microbiota","volume":"23","author":"Chen","year":"2024","journal-title":"Mol. Cancer"},{"issue":"10","key":"10.1016\/j.biopha.2025.118023_bib33","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1038\/s41593-024-01746-9","article-title":"VEGF-A-mediated venous endothelial cell proliferation results in neoangiogenesis during neuroinflammation","volume":"27","author":"Shahriar","year":"2024","journal-title":"Nat. Neurosci."},{"issue":"4","key":"10.1016\/j.biopha.2025.118023_bib34","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3390\/receptors3040021","article-title":"Receptor-Based Strategies for Overcoming Resistance in Cancer Therapy","volume":"3","author":"Sah","year":"2024","journal-title":"Receptors"},{"issue":"12","key":"10.1016\/j.biopha.2025.118023_bib35","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1002\/jcb.30344","article-title":"Molecular mechanism of VEGF and its role in pathological angiogenesis","volume":"123","author":"Ahmad","year":"2022","journal-title":"J. Cell. Biochem."},{"issue":"17","key":"10.1016\/j.biopha.2025.118023_bib36","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.2174\/13816128113199990590","article-title":"VEGF signaling in cancer treatment","volume":"20","author":"Sia","year":"2014","journal-title":"Curr. Pharm. Des."},{"issue":"4","key":"10.1016\/j.biopha.2025.118023_bib37","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.3390\/ijms19041232","article-title":"Resistance to anti-angiogenic therapy in cancer\u2014alterations to anti-VEGF pathway","volume":"19","author":"Itatani","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.biopha.2025.118023_bib38","article-title":"VEGF signaling: Role in angiogenesis and beyond","volume":"1879","author":"Shaw","year":"2024","journal-title":"Biochim. Et. Biophys. Acta (BBA) - Rev. Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2025.118023_bib39","first-page":"50","article-title":"Tumor angiogenesis and VEGFR-2: mechanism, pathways and current biological therapeutic interventions","volume":"22","author":"Shah","year":"2021","journal-title":"Curr. Drug Metab."},{"issue":"6","key":"10.1016\/j.biopha.2025.118023_bib40","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.tips.2014.03.001","article-title":"COX-2-derived endocannabinoid metabolites as novel inflammatory mediators","volume":"35","author":"Alhouayek","year":"2014","journal-title":"Trends Pharmacol. Sci."},{"issue":"6","key":"10.1016\/j.biopha.2025.118023_bib41","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.vph.2006.02.009","article-title":"Relationship between prostaglandin E2 and vascular endothelial growth factor (VEGF) in angiogenesis in human vascular endothelial cells","volume":"44","author":"Tamura","year":"2006","journal-title":"Vasc. Pharmacol."},{"issue":"3","key":"10.1016\/j.biopha.2025.118023_bib42","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S1479-666X(09)80042-5","article-title":"COX-2, VEGF and tumour angiogenesis","volume":"7","author":"Toomey","year":"2009","journal-title":"Surgeon"},{"issue":"5","key":"10.1016\/j.biopha.2025.118023_bib43","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.jobcr.2023.07.002","article-title":"Prostaglandin-endoperoxide synthase 2 (PTGS2) gene expression and its association with genes regulating the VEGF signaling pathway in head and neck squamous cell carcinoma","volume":"13","author":"Kamal","year":"2023","journal-title":"J. Oral. Biol. Craniofacial Res."},{"issue":"6","key":"10.1016\/j.biopha.2025.118023_bib44","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.jnutbio.2006.08.006","article-title":"Suppression of VEGF-mediated autocrine and paracrine interactions between prostate cancer cells and vascular endothelial cells by soy isoflavones","volume":"18","author":"Guo","year":"2007","journal-title":"J. Nutr. Biochem."},{"issue":"39","key":"10.1016\/j.biopha.2025.118023_bib45","doi-asserted-by":"crossref","first-page":"21610","DOI":"10.1021\/acs.jafc.4c05464","article-title":"Fucoxanthin attenuates angiogenesis by blocking the VEGFR2-mediated signaling pathway through binding the vascular endothelial growth factor","volume":"72","author":"Guo","year":"2024","journal-title":"J. Agric. Food Chem."},{"key":"10.1016\/j.biopha.2025.118023_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2024.117966","article-title":"A critical analysis of design, binding pattern and SAR of benzo-fused heteronuclear compounds as VEGFR-2 inhibitors","author":"Kashyap","year":"2024","journal-title":"Bioorg. Med. Chem."},{"issue":"5-2024","key":"10.1016\/j.biopha.2025.118023_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.51847\/tFgoN65qlJ","article-title":"Interaction of twenty-seven bicyclo derivatives with VEGF REceptors as A Therapeutic Alternative to Treat Cancer","volume":"13","author":"Lopez-Ramos","year":"2024","journal-title":"Clin. Cancer Investig. J."},{"issue":"2","key":"10.1016\/j.biopha.2025.118023_bib48","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s13105-024-01011-4","article-title":"Sorcin promotes proliferation of hepatocellular carcinoma by regulating VEGFA\/B via PI3K pathway","volume":"80","author":"Zhang","year":"2024","journal-title":"J. Physiol. Biochem."},{"issue":"3","key":"10.1016\/j.biopha.2025.118023_bib49","doi-asserted-by":"crossref","first-page":"49","DOI":"10.9734\/ajmah\/2024\/v22i3992","article-title":"Unraveling the significance of growth factors (TGF-\u03b2, PDGF, KGF, FGF, Pro Collagen, VEGF) in the dynamic of wound healing","volume":"22","author":"Firmansyah","year":"2024","journal-title":"Asian J. Med. Health"},{"issue":"12","key":"10.1016\/j.biopha.2025.118023_bib50","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1002\/ijc.34921","article-title":"Shaping the immune-suppressive microenvironment on tumor-associated myeloid cells through tumor-derived exosomes","volume":"154","author":"Wang","year":"2024","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.biopha.2025.118023_bib51","unstructured":"Lungu M., Lungu C.N., Mihailuta F., Hincu M.A. VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) UPREGULATION: MICRORNAS (miRNAs). 2024."},{"issue":"4","key":"10.1016\/j.biopha.2025.118023_bib52","doi-asserted-by":"crossref","first-page":"433","DOI":"10.18699\/vjgb-24-49","article-title":"Polymorphism of angiogenesis regulation factor genes (VEGF\/VEGFR), and extracellular matrix remodeling genes (MMP\/TIMP), and the levels of their products in extracellular tissues of patients with primary and secondary lymphedema","volume":"28","author":"Konenkov","year":"2024","journal-title":"Vavilov J. Genet. Breed."},{"issue":"1","key":"10.1016\/j.biopha.2025.118023_bib53","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12931-023-02637-6","article-title":"VEGF and EGFR signaling pathways are involved in the baicalein attenuation of OVA-induced airway inflammation and airway remodeling in mice","volume":"25","author":"Peng","year":"2024","journal-title":"Respir. Res."},{"issue":"7","key":"10.1016\/j.biopha.2025.118023_bib54","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.21873\/anticanres.17105","article-title":"Tumor Infiltrating Effector Regulatory T cells express VEGF receptor 2 in patients with colorectal cancer","volume":"44","author":"Tsumuraya","year":"2024","journal-title":"Anticancer Res."},{"key":"10.1016\/j.biopha.2025.118023_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117222","article-title":"MDSCs promote pathological angiogenesis in ocular neovascular disease","volume":"178","author":"Wu","year":"2024","journal-title":"Biomed. Pharmacother."},{"issue":"6","key":"10.1016\/j.biopha.2025.118023_bib56","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.3390\/ijms23063375","article-title":"Relationship between VEGF family members, their receptors and cell death in the neoplastic transformation of colorectal cancer","volume":"23","author":"Dakowicz","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.biopha.2025.118023_bib57","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1038\/s12276-020-00500-y","article-title":"Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity","volume":"52","author":"Lee","year":"2020","journal-title":"Exp. Mol. Med."},{"issue":"13","key":"10.1016\/j.biopha.2025.118023_bib58","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.3390\/cancers14133128","article-title":"Dynamic interactions between tumor cells and brain microvascular endothelial cells in glioblastoma","volume":"14","author":"Testa","year":"2022","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.biopha.2025.118023_bib59","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1002\/JLB.5RU0222-082R","article-title":"Direct and indirect regulation of the tumor immune microenvironment by VEGF","volume":"111","author":"Zhang","year":"2022","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.biopha.2025.118023_bib60","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2024.1387198","article-title":"Signaling crosstalk between tumor endothelial cells and immune cells in the microenvironment of solid tumors","volume":"12","author":"Xu","year":"2024","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.biopha.2025.118023_bib61","first-page":"30","article-title":"The lymphangiogenic growth factors VEGF-C and VEGF-D","volume":"17","author":"Krebs","year":"2013","journal-title":"LymphForsch"},{"issue":"12","key":"10.1016\/j.biopha.2025.118023_bib62","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1248\/bpb.34.1785","article-title":"Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy","volume":"34","author":"Takahashi","year":"2011","journal-title":"Biol. Pharm. Bull."},{"issue":"2","key":"10.1016\/j.biopha.2025.118023_bib63","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0304-3835(01)00762-5","article-title":"Hypoxia-inducible factor 1 alpha (HIF-1\u03b1) gene expression in human ovarian carcinoma","volume":"176","author":"Nakayama","year":"2002","journal-title":"Cancer Lett."},{"issue":"7","key":"10.1016\/j.biopha.2025.118023_bib64","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1161\/01.RES.0000243989.46006.b9","article-title":"Direct evidence for endothelial vascular endothelial growth factor receptor-1 function in nitric oxide\u2013mediated angiogenesis","volume":"99","author":"Ahmad","year":"2006","journal-title":"Circ. Res."},{"issue":"10","key":"10.1016\/j.biopha.2025.118023_bib65","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.3390\/cells10102655","article-title":"Regulation of T cells in cancer by nitric oxide","volume":"10","author":"Navasardyan","year":"2021","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.biopha.2025.118023_bib66","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1042\/CS20040370","article-title":"The vascular endothelial growth factor (VEGF)\/VEGF receptor system and its role under physiological and pathological conditions","volume":"109","author":"Takahashi","year":"2005","journal-title":"Clin. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2025.118023_bib67","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1158\/1078-0432.CCR-22-1366","article-title":"Molecular mechanisms and future implications of VEGF\/VEGFR in cancer therapy","volume":"29","author":"Patel","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2025.118023_bib68","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/978-3-540-73259-4_6","article-title":"Therapeutic anti-VEGF antibodies","author":"Lien","year":"2008","journal-title":"Ther. antibodies"},{"issue":"S5","key":"10.1016\/j.biopha.2025.118023_bib69","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1634\/theoncologist.9-90005-4","article-title":"Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response","volume":"9","author":"Vaupel","year":"2004","journal-title":"oncologist"},{"issue":"9","key":"10.1016\/j.biopha.2025.118023_bib70","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nrclinonc.2009.110","article-title":"Targeting angiogenesis: progress with anti-VEGF treatment with large molecules","volume":"6","author":"Grothey","year":"2009","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.biopha.2025.118023_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.jff.2024.106121","article-title":"Lithospermic acid promotes angiogenesis in zebrafish and HUVECs by regulating the VEGF\/PI3K-Akt\/MAPK signaling pathways","volume":"115","author":"Liang","year":"2024","journal-title":"J. Funct. Foods"},{"issue":"4","key":"10.1016\/j.biopha.2025.118023_bib72","doi-asserted-by":"crossref","first-page":"537","DOI":"10.4254\/wjh.v16.i4.537","article-title":"Multifaceted roles of lymphatic and blood endothelial cells in the tumor microenvironment of hepatocellular carcinoma: a comprehensive review","volume":"16","author":"Li","year":"2024","journal-title":"World J. Hepatol."},{"key":"10.1016\/j.biopha.2025.118023_bib73","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.semcancer.2022.03.011","article-title":"The impact of VEGF on cancer metastasis and systemic disease","volume":"86","author":"Yang","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.biopha.2025.118023_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2023.175586","article-title":"The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF","volume":"949","author":"Ghalehbandi","year":"2023","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.biopha.2025.118023_bib75","article-title":"Reassessing vascular endothelial growth factor (VEGF) in anti-angiogenic cancer therapy","volume":"32","author":"Elebiyo","year":"2022","journal-title":"Cancer Treat. Res. Commun."},{"issue":"5","key":"10.1016\/j.biopha.2025.118023_bib76","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.3390\/cancers12051172","article-title":"Inducing Angiogenesis, a key step in cancer vascularization, and treatment approaches","volume":"12","author":"Saman","year":"2020","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.biopha.2025.118023_bib77","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/s41392-021-00658-5","article-title":"Inflammation and tumor progression: signaling pathways and targeted intervention","volume":"6","author":"Zhao","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"issue":"8","key":"10.1016\/j.biopha.2025.118023_bib78","first-page":"3777","article-title":"Role of hypoxia in inhibiting dendritic cells by VEGF signaling in tumor microenvironments: mechanism and application","volume":"11","author":"Han","year":"2021","journal-title":"Am. J. Cancer Res"},{"issue":"9","key":"10.1016\/j.biopha.2025.118023_bib79","doi-asserted-by":"crossref","first-page":"4871","DOI":"10.3390\/ijms22094871","article-title":"Vascular endothelial growth factor, a key modulator of the anti-tumor immune response","volume":"22","author":"Geindreau","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.biopha.2025.118023_bib80","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1158\/2326-6066.CIR-19-0360","article-title":"Anti-VEGF treatment enhances CD8(+) T-cell antitumor activity by amplifying hypoxia","volume":"8","author":"de Almeida","year":"2020","journal-title":"Cancer Immunol. Res"},{"key":"10.1016\/j.biopha.2025.118023_bib81","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2024.101626","article-title":"Modulating cancer mechanopathology to restore vascular function and enhance immunotherapy","author":"Mpekris","year":"2024","journal-title":"Cell Rep. Med."},{"issue":"2","key":"10.1016\/j.biopha.2025.118023_bib82","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s10456-022-09863-4","article-title":"Proinflammatory activity of VEGF-targeted treatment through reversal of tumor endothelial cell anergy","volume":"26","author":"Nowak-Sliwinska","year":"2023","journal-title":"Angiogenesis"},{"issue":"1","key":"10.1016\/j.biopha.2025.118023_bib83","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13045-022-01347-8","article-title":"The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis","volume":"15","author":"Huang","year":"2022","journal-title":"J. Hematol. Oncol."},{"issue":"19","key":"10.1016\/j.biopha.2025.118023_bib84","doi-asserted-by":"crossref","first-page":"4325","DOI":"10.1242\/jcs.02552","article-title":"Epithelial-mesenchymal transition","volume":"118","author":"Radisky","year":"2005","journal-title":"J. Cell Sci."},{"issue":"1","key":"10.1016\/j.biopha.2025.118023_bib85","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s43018-023-00702-z","article-title":"Lipids as mediators of cancer progression and metastasis","volume":"5","author":"Vogel","year":"2024","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.biopha.2025.118023_bib86","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1509195","article-title":"Angiogenesis and EMT regulators in the tumor microenvironment in lung cancer and immunotherapy","volume":"15","author":"Yan","year":"2024","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.biopha.2025.118023_bib87","doi-asserted-by":"crossref","first-page":"10","DOI":"10.53964\/id.2024010","article-title":"Relevant MicroRNAs of MMPs and TIMPs with certain gut microbiota could be involved in the invasiveness and metastasis of malignant tumors","volume":"1","author":"Nakashima","year":"2024","journal-title":"Innov. Discov."},{"issue":"344","key":"10.1016\/j.biopha.2025.118023_bib88","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2005189","article-title":"Signaling mechanisms of the epithelial-mesenchymal transition","volume":"7","author":"Gonzalez","year":"2014","journal-title":"Sci. Signal."},{"issue":"1","key":"10.1016\/j.biopha.2025.118023_bib89","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11033-024-09996-3","article-title":"Harnessing the role of aberrant cell signaling pathways in glioblastoma multiforme: a prospect towards the targeted therapy","volume":"51","author":"Hasan","year":"2024","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.biopha.2025.118023_bib90","article-title":"VEGF Mediates Tumor Growth and Metastasis by Affecting the Expression of E-Cadherin and N-Cadherin Promoting Epithelial to Mesenchymal Transition in Gastric Cancer","volume":"17","author":"Zhang","year":"2023","journal-title":"Clin. Med. Insight.: Oncol."},{"key":"10.1016\/j.biopha.2025.118023_bib91","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/BF00437469","article-title":"Regulation of VEGF\/VPF expression in tumor cells: consequences for tumor growth and metastasis","volume":"15","author":"KP","year":"1996","journal-title":"Cancer Metastas-.-. Rev."},{"key":"10.1016\/j.biopha.2025.118023_bib92","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12964-019-0423-6","article-title":"Downregulation of exosomal CLEC3B in hepatocellular carcinoma promotes metastasis and angiogenesis via AMPK and VEGF signals","volume":"17","author":"Dai","year":"2019","journal-title":"Cell Commun. Signal."},{"issue":"22","key":"10.1016\/j.biopha.2025.118023_bib93","doi-asserted-by":"crossref","first-page":"E2900","DOI":"10.1073\/pnas.1503500112","article-title":"VEGF-B promotes cancer metastasis through a VEGF-A\u2013independent mechanism and serves as a marker of poor prognosis for cancer patients","volume":"112","author":"Yang","year":"2015","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"40","key":"10.1016\/j.biopha.2025.118023_bib94","doi-asserted-by":"crossref","first-page":"5609","DOI":"10.1038\/onc.2017.163","article-title":"KIF26B, a novel oncogene, promotes proliferation and metastasis by activating the VEGF pathway in gastric cancer","volume":"36","author":"Zhang","year":"2017","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.biopha.2025.118023_bib95","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1172\/JCI65385","article-title":"Tumor VEGF: VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer","volume":"123","author":"Chatterjee","year":"2013","journal-title":"J. Clin. Investig."},{"issue":"9","key":"10.1016\/j.biopha.2025.118023_bib96","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1080\/13543776.2017.1344215","article-title":"VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016)","volume":"27","author":"Peng","year":"2017","journal-title":"Expert Opin. Ther. Pat."},{"issue":"8","key":"10.1016\/j.biopha.2025.118023_bib97","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1158\/0008-5472.CAN-11-3406","article-title":"Anti-VEGF\/VEGFR therapy for cancer: reassessing the target","volume":"72","author":"Sitohy","year":"2012","journal-title":"Cancer Res."},{"issue":"16","key":"10.1016\/j.biopha.2025.118023_bib98","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1158\/0008-5472.CAN-11-4058","article-title":"VEGF exerts an angiogenesis-independent function in cancer cells to promote their malignant progression","volume":"72","author":"Cao","year":"2012","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.biopha.2025.118023_bib99","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1002\/hep.27236","article-title":"Autocrine vascular endothelial growth factor signaling promotes cell proliferation and modulates sorafenib treatment efficacy in hepatocellular carcinoma","volume":"60","author":"Peng","year":"2014","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.biopha.2025.118023_bib100","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.yexcr.2009.11.020","article-title":"VEGF elicits epithelial-mesenchymal transition (EMT) in prostate intraepithelial neoplasia (PIN)-like cells via an autocrine loop","volume":"316","author":"Gonzalez-Moreno","year":"2010","journal-title":"Exp. Cell Res."},{"issue":"12","key":"10.1016\/j.biopha.2025.118023_bib101","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3390\/cancers9120171","article-title":"Regulation of EMT in colorectal cancer: a culprit in metastasis","volume":"9","author":"Vu","year":"2017","journal-title":"Cancers"},{"issue":"24","key":"10.1016\/j.biopha.2025.118023_bib102","doi-asserted-by":"crossref","first-page":"7291","DOI":"10.7150\/jca.46429","article-title":"VEGF promotes migration and invasion by regulating EMT and MMPs in nasopharyngeal carcinoma","volume":"11","author":"Chen","year":"2020","journal-title":"J. Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2025.118023_bib103","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-36394-0","article-title":"A peptide mimicking the binding sites of VEGF-A and VEGF-B inhibits VEGFR-1\/-2 driven angiogenesis, tumor growth and metastasis","volume":"8","author":"Farzaneh Behelgardi","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2025.118023_bib104","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.omtn.2019.10.012","article-title":"Long noncoding RNA ASLNC07322 functions in VEGF-C expression regulated by Smad4 during colon cancer metastasis","volume":"18","author":"Li","year":"2019","journal-title":"Mol. Ther. -Nucleic Acids"},{"issue":"1","key":"10.1016\/j.biopha.2025.118023_bib105","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3233\/CBM-181287","article-title":"Correlations of TNM staging and lymph node metastasis of gastric cancer with MRI features and VEGF expression","volume":"23","author":"Pang","year":"2018","journal-title":"Cancer Biomark."},{"issue":"2","key":"10.1016\/j.biopha.2025.118023_bib106","first-page":"473","article-title":"Cystathionine\u2011\u03b3\u2011lyase promotes the metastasis of breast cancer via the VEGF signaling pathway","volume":"55","author":"Wang","year":"2019","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.biopha.2025.118023_bib107","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1007\/s12253-019-00755-5","article-title":"Caveolin-1 expression together with VEGF can be a predictor for lung metastasis and poor prognosis in osteosarcoma","volume":"26","author":"Mohamed","year":"2020","journal-title":"Pathol. Oncol. Res."},{"issue":"8","key":"10.1016\/j.biopha.2025.118023_bib108","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.7150\/jca.23769","article-title":"Oxytocin inhibits ovarian cancer metastasis by repressing the expression of MMP-2 and VEGF","volume":"9","author":"Ji","year":"2018","journal-title":"J. Cancer"},{"issue":"5","key":"10.1016\/j.biopha.2025.118023_bib109","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1038\/s41388-020-01539-x","article-title":"VEGF-C mediates tumor growth and metastasis through promoting EMT-epithelial breast cancer cell crosstalk","volume":"40","author":"Kong","year":"2021","journal-title":"Oncogene"},{"issue":"9","key":"10.1016\/j.biopha.2025.118023_bib110","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1158\/2159-8290.CD-15-0012","article-title":"Real-time imaging reveals local, transient vascular permeability, and tumor cell intravasation stimulated by TIE2hi macrophage\u2013derived VEGFA","volume":"5","author":"Harney","year":"2015","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.biopha.2025.118023_bib111","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1210\/edrv.18.1.0287","article-title":"The biology of vascular endothelial growth factor","volume":"18","author":"Ferrara","year":"1997","journal-title":"Endocr. Rev."},{"issue":"5","key":"10.1016\/j.biopha.2025.118023_bib112","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1084\/jem.174.5.1275","article-title":"Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: concentration in tumor blood vessels","volume":"174","author":"Dvorak","year":"1991","journal-title":"J. Exp. Med."},{"issue":"4","key":"10.1016\/j.biopha.2025.118023_bib113","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1083\/jcb.129.4.895","article-title":"Endothelial receptor tyrosine kinases involved in angiogenesis","volume":"129","author":"Mustonen","year":"1995","journal-title":"J. Cell Biol."},{"issue":"3-4","key":"10.1016\/j.biopha.2025.118023_bib114","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0079-6107(98)00047-9","article-title":"Structural analysis of receptor tyrosine kinases","volume":"71","author":"Hubbard","year":"1999","journal-title":"Prog. Biophys. Mol. Biol."},{"issue":"4","key":"10.1016\/j.biopha.2025.118023_bib115","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1517\/13543784.7.4.553","article-title":"Tyrosine kinases in disease: overview of kinase inhibitors as therapeutic agents and current drugs in clinical trials","volume":"7","author":"Strawn","year":"1998","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.biopha.2025.118023_bib116","series-title":"Translationally Controlled Tumor Protein Enhances Angiogenesis in Ovarian Tumors by Activating Vascular Endothelial Growth Factor Receptor 2 Signaling","author":"Rho","year":"2024"},{"issue":"6463","key":"10.1016\/j.biopha.2025.118023_bib117","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/367576a0","article-title":"Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant","volume":"367","author":"Millauer","year":"1994","journal-title":"Nature"},{"issue":"43","key":"10.1016\/j.biopha.2025.118023_bib118","doi-asserted-by":"crossref","first-page":"31047","DOI":"10.1074\/jbc.274.43.31047","article-title":"Vascular endothelial growth factor effect on endothelial cell proliferation, migration, and platelet-activating factor synthesis is Flk-1-dependent","volume":"274","author":"Bernatchez","year":"1999","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.biopha.2025.118023_bib119","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.3390\/ijms21041388","article-title":"Role of VEGFs\/VEGFR-1 signaling and its inhibition in modulating tumor invasion: experimental evidence in different metastatic cancer models","volume":"21","author":"Ceci","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2025.118023_bib120","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2165\/11317600-000000000-00000","article-title":"Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy","volume":"23","author":"Hsu","year":"2009","journal-title":"BioDrugs"},{"issue":"2","key":"10.1016\/j.biopha.2025.118023_bib121","doi-asserted-by":"crossref","first-page":"938","DOI":"10.7150\/thno.37443","article-title":"Monoclonal antibody-based molecular imaging strategies and theranostic opportunities","volume":"10","author":"Dammes","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.biopha.2025.118023_bib122","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s11523-017-0518-1","article-title":"Bevacizumab in colorectal cancer: current role in treatment and the potential of biosimilars","volume":"12","author":"Rosen","year":"2017","journal-title":"Target. Oncol."},{"key":"10.1016\/j.biopha.2025.118023_bib123","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102017","article-title":"Bevacizumab (Avastin\u00ae) in cancer treatment: A review of 15 years of clinical experience and future outlook","volume":"86","author":"Garcia","year":"2020","journal-title":"Cancer Treat. Rev."},{"issue":"1","key":"10.1016\/j.biopha.2025.118023_bib124","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3390\/biomedicines9010039","article-title":"Recent advances in monoclonal antibody therapy for colorectal cancers","volume":"9","author":"Hwang","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.biopha.2025.118023_bib125","first-page":"1","article-title":"Recent advances in ocular drug delivery systems and targeting VEGF receptors for management of ocular angiogenesis: a comprehensive review","volume":"7","author":"Narayana","year":"2021","journal-title":"Future J. Pharm. Sci."},{"key":"10.1016\/j.biopha.2025.118023_bib126","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1159\/000439008","article-title":"Fusion proteins: aflibercept (VEGF trap-eye)","volume":"55","author":"Sarwar","year":"2016","journal-title":"Retin. Pharmacother."},{"key":"10.1016\/j.biopha.2025.118023_bib127","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2024.102466","article-title":"Efficacy and safety of ramucirumab in gastric or gastroesophageal cancer: a systematic review and meta-analysis","author":"Wu","year":"2024","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"10.1016\/j.biopha.2025.118023_bib128","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.2147\/DDDT.S243787","article-title":"A first-in-human dose finding study of camrelizumab in patients with advanced or metastatic cancer in Australia","author":"Lickliter","year":"2020","journal-title":"Drug Des., Dev. Ther."},{"issue":"1","key":"10.1016\/j.biopha.2025.118023_bib129","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2077898","article-title":"Trial Watch: combination of tyrosine kinase inhibitors (TKIs) and immunotherapy","volume":"11","author":"Petrazzuolo","year":"2022","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.biopha.2025.118023_bib130","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s41392-022-01168-8","article-title":"Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective","volume":"7","author":"Yang","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"issue":"24","key":"10.1016\/j.biopha.2025.118023_bib131","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1038\/s41388-021-01841-2","article-title":"Receptor tyrosine kinases and cancer: oncogenic mechanisms and therapeutic approaches","volume":"40","author":"Saraon","year":"2021","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.biopha.2025.118023_bib132","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/nrd.2015.17","article-title":"Ten years of anti-vascular endothelial growth factor therapy","volume":"15","author":"Ferrara","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"issue":"31","key":"10.1016\/j.biopha.2025.118023_bib133","doi-asserted-by":"crossref","first-page":"3587","DOI":"10.1200\/JCO.21.02911","article-title":"Updated analysis of NEJ009: gefitinib-alone versus gefitinib plus chemotherapy for non\u2013small-cell lung cancer with mutated EGFR","volume":"40","author":"Miyauchi","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.biopha.2025.118023_bib134","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1159\/000488087","article-title":"Anti-angiogenics: current situation and future perspectives","volume":"41","author":"Zirlik","year":"2017","journal-title":"Oncol. Res. Treat."},{"issue":"1","key":"10.1016\/j.biopha.2025.118023_bib135","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/s41598-017-00839-9","article-title":"Leucovorin enhances the anti-cancer effect of bortezomib in colorectal cancer cells","volume":"7","author":"Wang","year":"2017","journal-title":"Sci. Rep."},{"issue":"23","key":"10.1016\/j.biopha.2025.118023_bib136","first-page":"8351","article-title":"Cyclooxygenase-2-selective nonsteroidal anti-inflammatory drugs inhibit hepatocyte growth factor\/scatter factor-induced angiogenesis","volume":"63","author":"Sengupta","year":"2003","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.biopha.2025.118023_bib137","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1146\/annurev.med.57.121304.131253","article-title":"NSAIDs and cancer prevention: targets downstream of COX-2","volume":"58","author":"Cha","year":"2007","journal-title":"Annu Rev. Med"},{"key":"10.1016\/j.biopha.2025.118023_bib138","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2407-13-273","article-title":"Celecoxib alleviates tamoxifen-instigated angiogenic effects by ROS-dependent VEGF\/VEGFR2 autocrine signaling","volume":"13","author":"Kumar","year":"2013","journal-title":"Bmc Cancer"},{"issue":"8","key":"10.1016\/j.biopha.2025.118023_bib139","doi-asserted-by":"crossref","first-page":"6341","DOI":"10.18632\/oncotarget.3437","article-title":"Cyclooxygenase-2 blockade can improve efficacy of VEGF-targeting drugs","volume":"6","author":"Ben-Batalla","year":"2015","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.biopha.2025.118023_bib140","doi-asserted-by":"crossref","first-page":"186","DOI":"10.4103\/0976-500X.136098","article-title":"Metronomic chemotherapy","volume":"5","author":"Maiti","year":"2014","journal-title":"J. Pharmacol. Pharmacother."},{"key":"10.1016\/j.biopha.2025.118023_bib141","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.572861","article-title":"Metronomic celecoxib therapy in clinically available dosage ablates hepatocellular carcinoma via suppressing cell invasion, growth, and stemness in pre-clinical models","volume":"10","author":"Yeh","year":"2020","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118023_bib142","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.breast.2010.07.004","article-title":"Selective cyclooxygenase-2 (COX-2) inhibitors and breast cancer risk","volume":"20","author":"Ashok","year":"2011","journal-title":"Breast"},{"issue":"17","key":"10.1016\/j.biopha.2025.118023_bib143","doi-asserted-by":"crossref","first-page":"13618","DOI":"10.3390\/ijms241713618","article-title":"Targeted therapy for cancers: from ongoing clinical trials to FDA-approved drugs","volume":"24","author":"Choi","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.biopha.2025.118023_bib144","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1172\/JCI96582","article-title":"Increased vessel perfusion predicts the efficacy of immune checkpoint blockade","volume":"128","author":"Zheng","year":"2018","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.biopha.2025.118023_bib145","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.689132","article-title":"The combination of immune checkpoint blockade and angiogenesis inhibitors in the treatment of advanced non-small cell lung cancer","volume":"12","author":"Ren","year":"2021","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118023_bib146","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/s13046-019-1259-z","article-title":"Combination of CTLA-4 and PD-1 blockers for treatment of cancer","volume":"38","author":"Rotte","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2025.118023_bib147","unstructured":"Ruyssen N. THERAPY-INDUCED METASTASIS: Ghent University; 2019."},{"issue":"21","key":"10.1016\/j.biopha.2025.118023_bib148","doi-asserted-by":"crossref","first-page":"8086","DOI":"10.1002\/cam4.3410","article-title":"Study and analysis of antitumor resistance mechanism of PD1\/PD-L1 immune checkpoint blocker","volume":"9","author":"Wang","year":"2020","journal-title":"Cancer Med."},{"key":"10.1016\/j.biopha.2025.118023_bib149","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.964442","article-title":"The role of PD-1\/PD-L1 and application of immune-checkpoint inhibitors in human cancers","volume":"13","author":"Tang","year":"2022","journal-title":"Front. Immunol."},{"issue":"16","key":"10.1016\/j.biopha.2025.118023_bib150","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.21037\/atm-20-2037","article-title":"Metabolic reprograming of tumor-associated macrophages","volume":"8","author":"Puthenveetil","year":"2020","journal-title":"Ann. Transl. Med."},{"issue":"11","key":"10.1016\/j.biopha.2025.118023_bib151","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1200\/JCO.19.01598","article-title":"Phase IB\/II trial of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma, endometrial cancer, and other selected advanced solid tumors","volume":"38","author":"Taylor","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.biopha.2025.118023_bib152","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.biopha.2025.118023_bib153","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S1470-2045(18)30107-4","article-title":"Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial","volume":"19","author":"Choueiri","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.biopha.2025.118023_bib154","article-title":"Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis","volume":"362","author":"Shen","year":"2018","journal-title":"Bmj"},{"issue":"1","key":"10.1016\/j.biopha.2025.118023_bib155","article-title":"Association between neutrophil-to-eosinophil ratio and efficacy outcomes with avelumab plus axitinib or sunitinib in patients with advanced renal cell carcinoma: post hoc analyses from the JAVELIN Renal 101 trial","volume":"3","author":"Tucker","year":"2024","journal-title":"BMJ Oncol."},{"key":"10.1016\/j.biopha.2025.118023_bib156","doi-asserted-by":"crossref","first-page":"7321","DOI":"10.2147\/CMAR.S216605","article-title":"Pembrolizumab in combination with axitinib as first-line treatment for patients with renal cell carcinoma (RCC): evidence to date","author":"Chau","year":"2020","journal-title":"Cancer Manag. Res."},{"issue":"5","key":"10.1016\/j.biopha.2025.118023_bib157","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/PPO.0000000000000471","article-title":"The immunotherapy revolution in kidney cancer treatment: scientific rationale and first-generation results","volume":"26","author":"Hasanov","year":"2020","journal-title":"Cancer J."},{"issue":"24","key":"10.1016\/j.biopha.2025.118023_bib158","doi-asserted-by":"crossref","first-page":"15585","DOI":"10.3390\/ijms232415585","article-title":"The VEGF\/VEGFR axis revisited: implications for cancer therapy","volume":"23","author":"Mabeta","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2025.118023_bib159","doi-asserted-by":"crossref","first-page":"476","DOI":"10.36660\/abc.20190902","article-title":"VEGF121 mediates post-hypoxia cardioprotective effects via CaSR and mitochondria-dependent protease pathway","volume":"117","author":"Zhang","year":"2021","journal-title":"Arq. Bras. De. Cardiol."},{"key":"10.1016\/j.biopha.2025.118023_bib160","doi-asserted-by":"crossref","first-page":"v11","DOI":"10.1093\/annonc\/mdy151.038","article-title":"Vascular endothelial growth factor (VEGF) splice isoforms may hold the key to targeting tumour angiogenesis in oesophageal cancer","volume":"29","author":"Mehedi","year":"2018","journal-title":"Ann. Oncol."},{"issue":"7","key":"10.1016\/j.biopha.2025.118023_bib161","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1002\/jbm.a.37483","article-title":"Functional recovery of myocardial infarction by specific EBP-PR1P peptides bridging injectable cardiac extracellular matrix and vascular endothelial growth factor","volume":"111","author":"Cao","year":"2023","journal-title":"J. Biomed. Mater. Res. Part A"},{"key":"10.1016\/j.biopha.2025.118023_bib162","article-title":"The splicing factor kinase SRPK1 is a therapeutic target for Peripheral Vascular Disease","volume":"2024","author":"Bhalla","year":"2024","journal-title":"bioRxiv"},{"key":"10.1016\/j.biopha.2025.118023_bib163","doi-asserted-by":"crossref","unstructured":"Chen Y., Li X., Wen H., Lu M., Adlat S., Li D., et al. Inactivation of VEGFB Blocks Tumor Growth and Metastasis by Skewing Macrophages to M1 Phenotype. 2022.","DOI":"10.21203\/rs.3.rs-1795655\/v1"},{"issue":"2","key":"10.1016\/j.biopha.2025.118023_bib164","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s13402-022-00665-w","article-title":"How VEGF-A and its splice variants affect breast cancer development\u2013clinical implications","volume":"45","author":"Al Kawas","year":"2022","journal-title":"Cell. Oncol."},{"issue":"18","key":"10.1016\/j.biopha.2025.118023_bib165","doi-asserted-by":"crossref","first-page":"4652","DOI":"10.3390\/cancers13184652","article-title":"Functional characteristics and regulated expression of alternatively spliced tissue factor: an update","volume":"13","author":"Matiash","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2025.118023_bib166","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/1744-9987.13803","article-title":"Induction of vascular endothelial growth factor-A165a in human retinal and endothelial cells in response to glyoxal","volume":"26","author":"Morawietz","year":"2022","journal-title":"Ther. Apher. Dial."},{"issue":"11","key":"10.1016\/j.biopha.2025.118023_bib167","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.clml.2021.06.020","article-title":"Panobinostat from bench to bedside: rethinking the treatment paradigm for multiple myeloma","volume":"21","author":"Berdeja","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"3","key":"10.1016\/j.biopha.2025.118023_bib168","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1210\/jc.2007-1714","article-title":"Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study","volume":"93","author":"Elisei","year":"2008","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"19","key":"10.1016\/j.biopha.2025.118023_bib169","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1510016","article-title":"Cabozantinib versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Choueiri","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.biopha.2025.118023_bib170","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1717002","article-title":"Cabozantinib in patients with advanced and progressing hepatocellular carcinoma","volume":"379","author":"Abou-Alfa","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.biopha.2025.118023_bib171","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"23","key":"10.1016\/j.biopha.2025.118023_bib172","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1056\/NEJMoa1611406","article-title":"Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy","volume":"375","author":"Ravaud","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"9544","key":"10.1016\/j.biopha.2025.118023_bib173","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(06)69446-4","article-title":"Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial","volume":"368","author":"Demetri","year":"2006","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.biopha.2025.118023_bib174","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1634\/theoncologist.2012-0044","article-title":"FDA approval summary: sunitinib for the treatment of progressive well-differentiated locally advanced or metastatic pancreatic neuroendocrine tumors","volume":"17","author":"Blumenthal","year":"2012","journal-title":"oncologist"},{"issue":"6","key":"10.1016\/j.biopha.2025.118023_bib175","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial","volume":"28","author":"Sternberg","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"9829","key":"10.1016\/j.biopha.2025.118023_bib176","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","article-title":"Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"379","author":"Van Der Graaf","year":"2012","journal-title":"Lancet"},{"issue":"9863","key":"10.1016\/j.biopha.2025.118023_bib177","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Grothey","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2025.118023_bib178","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s10147-015-0790-y","article-title":"Regorafenib for advanced gastrointestinal stromal tumors following imatinib and sunitinib treatment: a subgroup analysis evaluating Japanese patients in the phase III GRID trial","volume":"20","author":"Komatsu","year":"2015","journal-title":"Int. J. Clin. Oncol."},{"issue":"10064","key":"10.1016\/j.biopha.2025.118023_bib179","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.biopha.2025.118023_bib180","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.biopha.2025.118023_bib181","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"9940","key":"10.1016\/j.biopha.2025.118023_bib182","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","article-title":"Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial","volume":"384","author":"Brose","year":"2014","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.biopha.2025.118023_bib183","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"15","key":"10.1016\/j.biopha.2025.118023_bib184","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/S1470-2045(15)00290-9","article-title":"Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial","volume":"16","author":"Motzer","year":"2015","journal-title":"Lancet Oncol."},{"issue":"10126","key":"10.1016\/j.biopha.2025.118023_bib185","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.biopha.2025.118023_bib186","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"16","key":"10.1016\/j.biopha.2025.118023_bib187","doi-asserted-by":"crossref","first-page":"R921","DOI":"10.1016\/j.cub.2020.06.081","article-title":"The tumor microenvironment","volume":"30","author":"Anderson","year":"2020","journal-title":"Curr. Biol."},{"issue":"30","key":"10.1016\/j.biopha.2025.118023_bib188","doi-asserted-by":"crossref","first-page":"2008094","DOI":"10.1002\/adma.202008094","article-title":"From design to clinic: engineered nanobiomaterials for immune normalization therapy of cancer","volume":"33","author":"Saeed","year":"2021","journal-title":"Adv. Mater."},{"issue":"9","key":"10.1016\/j.biopha.2025.118023_bib189","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.3390\/cells10092201","article-title":"Engineering a vascularized hypoxic tumor model for therapeutic assessment","volume":"10","author":"Ando","year":"2021","journal-title":"Cells"},{"issue":"7","key":"10.1016\/j.biopha.2025.118023_bib190","doi-asserted-by":"crossref","first-page":"3728","DOI":"10.1073\/pnas.1919764117","article-title":"Combining microenvironment normalization strategies to improve cancer immunotherapy","volume":"117","author":"Mpekris","year":"2020","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"11","key":"10.1016\/j.biopha.2025.118023_bib191","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1016\/j.drudis.2021.07.024","article-title":"Recent advances in, and challenges of, anti-angiogenesis agents for tumor chemotherapy based on vascular normalization","volume":"26","author":"Wang","year":"2021","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.biopha.2025.118023_bib192","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1007\/s11255-020-02474-2","article-title":"Recent advances in understanding the role of hypoxia-inducible factor 1\u03b1 in renal fibrosis","volume":"52","author":"Wei","year":"2020","journal-title":"Int. Urol. Nephrol."},{"key":"10.1016\/j.biopha.2025.118023_bib193","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.649630","article-title":"Regulation of endothelial and vascular functions by carbon monoxide via crosstalk with nitric oxide","volume":"8","author":"Choi","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"issue":"2","key":"10.1016\/j.biopha.2025.118023_bib194","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s10637-021-01201-7","article-title":"Boron neutron capture therapy using dodecaborated albumin conjugates with maleimide is effective in a rat glioma model","volume":"40","author":"Kashiwagi","year":"2022","journal-title":"Investig. N. Drugs"},{"key":"10.1016\/j.biopha.2025.118023_bib195","doi-asserted-by":"crossref","DOI":"10.1177\/1533033820980116","article-title":"Tumor vessel normalization: a window to enhancing cancer immunotherapy","volume":"19","author":"Li","year":"2020","journal-title":"Technol. Cancer Res. Treat."},{"key":"10.1016\/j.biopha.2025.118023_bib196","unstructured":"Fierro-Hern\u00e1ndez P. Optimization of tumor immunotherapy in breast carcinoma. Tumor microvasculature normalization: blood vessels' endothelium. 2021."},{"key":"10.1016\/j.biopha.2025.118023_bib197","series-title":"Receptor Tyrosine Kinases in Neurodegenerative and Psychiatric Disorders","first-page":"117","article-title":"Receptor tyrosine kinases (RTKs): from biology to pathophysiology","author":"Batool","year":"2023"},{"key":"10.1016\/j.biopha.2025.118023_bib198","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.bbrc.2021.03.166","article-title":"Direct interaction of the ATP-sensitive K+\u2009channel by the tyrosine kinase inhibitors imatinib, sunitinib and nilotinib","volume":"557","author":"Fr\u00f6bom","year":"2021","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"8","key":"10.1016\/j.biopha.2025.118023_bib199","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1080\/14728222.2023.2248381","article-title":"Targeting HIF-1 for prostate cancer: a synthesis of preclinical evidence","volume":"27","author":"Zohar","year":"2023","journal-title":"Expert Opin. Ther. Targets"},{"issue":"1","key":"10.1016\/j.biopha.2025.118023_bib200","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2174\/1568009619666191114110359","article-title":"Anti-VEGF\/VEGFR2 monoclonal antibodies and their combinations with PD-1\/PD-L1 inhibitors in clinic","volume":"20","author":"Gao","year":"2020","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.biopha.2025.118023_bib201","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1276694","article-title":"Vascular normalization: reshaping the tumor microenvironment and augmenting antitumor immunity for ovarian cancer","volume":"14","author":"Yu","year":"2023","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.biopha.2025.118023_bib202","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202216128","article-title":"Shear stress control of vascular leaks and atheromas through Tie2 activation by VE-PTP sequestration","volume":"15","author":"Shirakura","year":"2023","journal-title":"EMBO Mol. Med."},{"issue":"10","key":"10.1016\/j.biopha.2025.118023_bib203","doi-asserted-by":"crossref","DOI":"10.1242\/dmm.036236","article-title":"Immune regulation of metastasis: mechanistic insights and therapeutic opportunities","volume":"11","author":"Blomberg","year":"2018","journal-title":"Dis. Models Mech."},{"issue":"22","key":"10.1016\/j.biopha.2025.118023_bib204","doi-asserted-by":"crossref","first-page":"5621","DOI":"10.3390\/cancers13225621","article-title":"The role of the innate immune system in cancer dormancy and relapse","volume":"13","author":"Chernosky","year":"2021","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.biopha.2025.118023_bib205","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1007\/s00210-023-02781-2","article-title":"Effects of chemotherapy on the immune system: implications for cancer treatment and patient outcomes","volume":"397","author":"Sharma","year":"2024","journal-title":"Naunyn-Schmiede 'S. Arch. Pharmacol."},{"key":"10.1016\/j.biopha.2025.118023_bib206","doi-asserted-by":"crossref","first-page":"202","DOI":"10.3389\/fonc.2015.00202","article-title":"Inhibition of immune checkpoints and vascular endothelial growth factor as combination therapy for metastatic melanoma: an overview of rationale, preclinical evidence, and initial clinical data","volume":"5","author":"Ott","year":"2015","journal-title":"Front. Oncol."},{"issue":"6","key":"10.1016\/j.biopha.2025.118023_bib207","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.3390\/cancers13061422","article-title":"Role of bFGF in Acquired Resistance upon Anti-VEGF Therapy in Cancer","volume":"13","author":"Zahra","year":"2021","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.biopha.2025.118023_bib208","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.109979","article-title":"Hallmarks of cancer resistance","volume":"27","author":"Tufail","year":"2024","journal-title":"iScience"},{"issue":"17","key":"10.1016\/j.biopha.2025.118023_bib209","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.3390\/cancers16172975","article-title":"Recent treatment strategies and molecular pathways in resistance mechanisms of antiangiogenic therapies in glioblastoma","volume":"16","author":"Rahman","year":"2024","journal-title":"Cancers"},{"issue":"11","key":"10.1016\/j.biopha.2025.118023_bib210","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1093\/jnci\/djt093","article-title":"Effect of tumor microenvironment on tumor VEGF during anti-VEGF treatment: systems biology predictions","volume":"105","author":"Finley","year":"2013","journal-title":"JNCI: J. Natl. Cancer Inst."},{"key":"10.1016\/j.biopha.2025.118023_bib211","series-title":"OBSOLETE: Computational Systems Biology for the VEGF Family in Angiogenesis","author":"Imoukhuede","year":"2018"},{"issue":"6","key":"10.1016\/j.biopha.2025.118023_bib212","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s10142-024-01493-x","article-title":"Multi-omics analysis of the biological function of the VEGF family in colon adenocarcinoma","volume":"24","author":"Yang","year":"2024","journal-title":"Funct. Integr. Genom."},{"key":"10.1016\/j.biopha.2025.118023_bib213","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2022.105511","article-title":"Modeling the efficacy of different anti-angiogenic drugs on treatment of solid tumors using 3D computational modeling and machine learning","volume":"146","author":"Mousavi","year":"2022","journal-title":"Comput. Biol. Med."},{"issue":"12","key":"10.1016\/j.biopha.2025.118023_bib214","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1007\/s40265-020-01327-7","article-title":"Immunomodulatory Roles of VEGF Pathway Inhibitors in Renal Cell Carcinoma","volume":"80","author":"Hirsch","year":"2020","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.biopha.2025.118023_bib215","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/s41392-023-01460-1","article-title":"Angiogenic signaling pathways and anti-angiogenic therapy for cancer","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.biopha.2025.118023_bib216","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13045-021-01034-0","article-title":"The integration of immune checkpoint inhibitors with VEGF targeted agents in advanced gastric and gastroesophageal adenocarcinoma: a review on the rationale and results of early phase trials","volume":"14","author":"Saeed","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.biopha.2025.118023_bib217","article-title":"Liquid biopsy in cancer management: integrating diagnostics and clinical applications","volume":"43","author":"Pandey","year":"2025","journal-title":"Pract. Lab. Med."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225002173?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225002173?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T22:55:04Z","timestamp":1781823304000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225002173"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":217,"alternative-id":["S0753332225002173"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118023","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting VEGF signaling for tumor microenvironment remodeling and metastasis inhibition: Therapeutic strategies and insights","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118023"}}